Results 41 to 50 of about 21,842 (260)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Asenapine versus olanzapine for the treatment of nausea and vomiting in patients with cancer: A retrospective study

Neuropsychopharmacology Reports
Aim Patients with cancer often experience nausea and vomiting (N/V), but may have difficulty using olanzapine (OLZ), a common antiemetic. Asenapine (ASE) is a multi‐acting receptor‐targeted antipsychotic like OLZ, although there is little evidence that ...
Tomohiko Kimura, Akifumi Kanai, Hiroyuki Muraoka, Yuichiro Takahashi, Masatomo Ara, Ken Inada   +5 more
doaj   +1 more source

Chemotherapy‐Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline‐Free Regimen With Docetaxel, Cyclophosphamide—Results From a Randomized Clinical Trial

International Journal of Cancer, EarlyView.
Chemotherapy‐induced nausea and vomiting (CINV) remains a significant clinical problem despite modern antiemetics. In particular, antiemetic strategies for emerging cancer therapies lack detailed evaluation. This randomized trial analyzed hourly CINV data for patients with early breast cancer who received either docetaxel plus cyclophosphamide (TC) or ...
Manuel Hörner, Henning Schäffler, Lothar Häberle, Chloë Goossens, Kerstin Pfister, Elena Leinert, Kristina Veselinovic, Sara Y. Brucker, Uwe Köhler, Georg Heinrich, Andreas Schneeweiss, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Brigitte Rack, Sabine Heublein, Philipp Ziegler   +16 more
wiley   +1 more source

Dose Optimization of Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Is the Prophylactic Use of an Antiemetic Necessary?

Journal of Parkinson’s Disease, 2023
Background: Nausea is common upon initiating dopamine agonists in patients with Parkinson’s disease (PD); however, pretreatment with an antiemetic is recommended only when initiating apomorphine formulations. Objective: Evaluate the need for prophylactic
Robert A. Hauser, William G. Ondo, Yi Zhang, Alyssa Bowling, Bradford Navia, Eric Pappert, Stuart H. Isaacson,   +7 more
doaj   +1 more source

Multi‐omics biomarkers for intestinal infection and inflammation in inflammatory bowel disease: Current evidence, translational challenges, and diagnostic opportunities

Interdisciplinary Medicine, EarlyView.
Prospective multi‐site cohorts, multi‐omics profiling, and computational analysis may help identify biomarker patterns across clinical settings in IBD and superimposed infections. With further mechanistic and clinical validation, these signals could support the development of practical multi‐analyte tools for more precise diagnosis and management ...
Ziyu Yang, Jiayi Yao, Xinxian Zhao, Yan Xu, Yifan Chen, Tianchi Chen, Ying Jian, Min Li   +7 more
wiley   +1 more source

State of the art of antiemetic therapy

, 2018
Despite relevant progress achieved in the last 30 years for the prevention of chemotherapy-induced emesis, nausea and vomiting continue to be among the most distressing adverse events induced by chemotherapy.
Roila F., Fatigoni S.
core   +1 more source

Postoperative Effects of Celecoxib on Opioid Use and Pain Control After Benign Oropharyngeal Surgery

The Laryngoscope, EarlyView.
This study evaluated how the addition of celecoxib to a multimodal pain regimen following tonsillectomy + adenoidectomy, or uvulopalatopharyngoplasty (UPPP) + tonsillectomy affects postoperative opioid use and pain control. Patients who received celecoxib consumed significantly fewer opioids compared to the historic control group, with similar ...
Alana Platukus, Praneet Kaki, Anastasia Kaffenes, Udeerna Tippabhatla, Jared Robinson, Jaehee Kim, Erin Creighton, Meghan Crippen, Maurits Boon, Colin Huntley   +9 more
wiley   +1 more source

The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial

Frontiers in Endocrinology
ObjectiveThe present study was to investigate three different single-drug regimens to show which was more effective to reduce radioactive iodine therapy (RAI) associated nausea and vomiting, and to compare the occurrence of long-term gastrointestinal ...
Xiao Li, Jingjia Cao, Wenxiu Wang, Xiaolu Zhu, Yaru Sun, Lei Song, Wei Zhang, Yong Han   +7 more
doaj   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

Cancer Medicine, 2020
NEPA is the only fixed combination antiemetic, comprised of an NK1RA (netupitant) and a 5‐HT3RA (palonosetron). In the first head‐to‐head trial to compare NK1RA‐containing regimens, a single oral dose of NEPA was non‐inferior to a 3‐day aprepitant ...
Jianhua Chang, Gongyan Chen, Dong Wang, Guihua Wang, Shun Lu, Jifeng Feng, Wei Li, Ping Li, Corinna Lanzarotti, Salvatore Chessari, Li Zhang   +10 more
doaj   +1 more source